Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension
BET inhibitor
Pulmonary artery banding
Hypoxia
DOI:
10.1164/rccm.201812-2275oc
Publication Date:
2019-05-01T19:36:22Z
AUTHORS (20)
ABSTRACT
Rationale: Pulmonary arterial hypertension (PAH) is a degenerative arteriopathy that leads to right ventricular (RV) failure. BRD4 (bromodomain-containing protein 4), member of the BET (bromodomain and extra-terminal motif) family, has been identified as critical epigenetic driver for cardiovascular diseases.Objectives: To explore therapeutic potential in PAH RVX208, clinically available inhibitor.Methods: Microvascular endothelial cells, smooth muscle cells isolated from distal pulmonary arteries patients with PAH, rats Sugen5416 + hypoxia- or monocrotaline shunt-induced RV pressure overload induced by artery banding were treated RVX208 three independent laboratories.Measurements Main Results: upregulated remodeled vasculature where it regulates FoxM1 PLK1, proteins implicated DNA damage response. normalized hyperproliferative, apoptosis-resistant, inflammatory phenotype microvascular PAH. Oral treatment reversed vascular remodeling improved hemodynamics two trials hypoxia-PAH shunt-PAH. could be combined safely contemporary standard care. also supported pressure-loaded rats.Conclusions: inhibitor, modulates proproliferative, prosurvival, proinflammatory pathways, potentially through interactions PLK1. This vitro, diverse rat models. vivo. Together, these data support establishment clinical trial
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (30)
CITATIONS (114)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....